Intersect ENT Reports First Quarter 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Intersect ENT (XENT) PT Raised to $22 at Northland Capital Markets; Medicare Cuts Not Hurting
May 3, 2017 12:25 PM EDTNorthland Capital Markets raised its price target on Intersect ENT (NASDAQ: XENT) to $22.00 (from $17.00) while maintaining a Outperform rating. The firm also raised FY18 numbers.
Analyst Suraj Kalia notes strong growth persists despite Medicare fears. Kalia said commentary indicated relatively muted effect on... More
Intersect ENT (XENT) Tops Q1 EPS by 2c
May 2, 2017 4:14 PM EDTIntersect ENT (NASDAQ: XENT) reported Q1 EPS of ($0.23), $0.02 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $20.5 million versus the consensus estimate of $19.38 million.
GUIDANCE:
Intersect ENT sees Q2 2017 revenue of $22.5-22.7 million, versus the... More
